Lilly Q3 Profit Rises 16%; Lifts FY26 Sales View, Trims Adjusted Earnings Outlook

Eli Lilly (LLY) reported Q3 net income of $6.45B (+16% YoY) and revenue of $24.40B (+39% YoY), driven by Mounjaro and Zepbound sales. The company raised its FY26 revenue outlook to $91B-$92B but lowered adjusted EPS guidance to $35.00-$36.00 due to acquisition-related charges. Shares rose 4.02% in pre-market trading.

Original reporting
Published Oct 29, 2026, 11:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The earnings beat and raised revenue guidance drove a 4% pre‑market rally, while the earnings guidance trim may limit further upside.

02

Market read

Large‑cap biotech earnings with mixed guidance provide a short‑term trading opportunity and longer‑term sector implications.

03

What to watch

Acquired in‑process R&D charges and integration costs could weigh on near‑term profitability more than reflected in the guidance.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Eli Lilly's Q3 results feature strong sales from Mounjaro and Zepbound, significant revenue growth, and a revised performance margin outlook.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly reported Q3 results with 16% profit rise, raised FY26 revenue outlook, and trimmed adjusted earnings guidance.

Expected impact

modest upside as market prices in higher revenue outlook, with potential pressure from lower earnings guidance

Evidence & confidence

Revenue guidance increase signals growth, while earnings guidance reduction introduces downside risk; the net effect is a slight positive bias reflected in the pre‑market rally.

Market effects

Strong performance reinforces bullish sentiment for the biotech/pharma sector, especially diabetes and obesity drug markets.

Positive for US large‑cap biotech stocks, may lift broader Nasdaq health‑care index.

Highlights continued demand for obesity treatments worldwide, could influence global pharma peers.

Counterpoint

Investors may view the earnings guidance cut as a red flag, suggesting margin pressure despite revenue growth.

Key entities

  • Eli Lilly and Company

    US‑listed pharmaceutical company reporting Q3 results.

Related articles

$NVOLow

GLP-1 vision warning: Could demand be affected?

The FDA requires GLP-1 drugs to carry warnings about a potential increased risk of NAION, a condition that can cause vision loss. Analysis showed 6.4 cases per 100,000 person-years among users, though no causal link has been established. Experts believe the warnings will have limited impact on demand. Novo Nordisk and Eli Lilly, manufacturers of GLP-1 drugs, responded to the FDA's requirements, emphasizing patient safety and the lack of specific findings related to their medicines.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$LLYMed

ACR: Retatrutide Beneficial in Adults With Painful Knee OA, Obesity

A study published in the New England Journal of Medicine found that retatrutide, developed by Eli Lilly, significantly reduced knee pain and body weight in adults with painful knee osteoarthritis and obesity compared to placebo. The trials showed mean WOMAC pain score reductions of -3.96 and -3.74 for 9mg and 12mg doses, respectively, versus -2.12 for placebo, and weight reductions of -20.0% and -23.7% versus -4.6%. Serious adverse events were more common with retatrutide.

$LLYMed

Health Canada approves Eli Lilly’s daily Foundayo pill for weight loss

Health Canada approved Eli Lilly's daily oral weight-loss pill, Foundayo, for adults with obesity or related conditions. The drug, expected in January, competes with Lilly's injectables and Novo Nordisk's Rybelsus. Foundayo offers meal flexibility and differs chemically from other GLP-1 drugs. Pricing and insurance coverage will impact patient choices, with clinical trials showing varying weight-loss results.

$NVOHigh

What to know about the new GLP-1 pills now on sale

Novo Nordisk's Wegovy and Lilly's Foundayo, oral GLP-1 weight loss pills, are now available in Australia. Experts anticipate increased demand but caution about long-term effects and misuse. Prices range from $250 to $395 monthly, comparable to injectable versions. Availability varies by pharmacy.